CD44V6 expression in human colorectal carcinoma

Coppola, Domenico; Hyacinthe, Micheline; Fu, Lei; Cantor, Alan; Karl, Richard C.; Marcet, Jorge; Cooper, David L.; Nicosia, Santo V.; Cooper, Harry S.

doi:10.1016/s0046-8177(98)80014-2

Cited by 60 publications

(55 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hakam et al [25]reported that insulin-like growth factor 1 receptor was highly positive in both primary (96%) and metastatic sites (93%), whereas Coppola et al [26]reported scanty expression of CD44V6 in metastatic tumors (38%) in spite of a strong expression at the primary site (91%). In this study, metastatic tumors were completely negative for MT although the surrounding liver strongly expressed MT.…”

Section: Discussionmentioning

confidence: 99%

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Hishikawa¹,

Kohno²,

Ueda³

et al. 2001

Oncology

View full text Add to dashboard Cite

The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis. Immunohistochemical staining for MT was performed on the specimens of adenocarcinoma of the colon and rectum and its liver metastases in 34 patients treated with curative surgery, respectively. Expression of MT was compared with clinicopathological variables and patient survival. In patients with primary colorectal cancer, positive expression was found in 7 of 34 (20.6%) patients, but MT was not detected in any of the cases of liver metastases (0%; p = 0.0111). In the primary tumor, positive MT expression was significantly associated with a higher degree of lymph node involvement (mean ± SD: 48.4 ± 33.8 vs. 18.6 ± 24.4% in MT-positive and MT-negative tumors, respectively; p = 0.0122). The survival rate in the patients with MT-negative tumors was significantly better than that in those with MT-positive tumors as primary sites (p = 0.0198). MT expression in colorectal cancer may be a potential marker affecting lymph node metastases and may be a predictor of a poor prognosis, particularly in patients with synchronous liver metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Hishikawa¹,

Kohno²,

Ueda³

et al. 2001

Oncology

View full text Add to dashboard Cite

show abstract

“…Alternative splicings of the CD44 standard form gene, occurring between Exons 5 and 16, gives rise to many CD44 isoforms (CD44v). There has been interest in the expression of CD44 as a marker of tumor aggressiveness and metastatic potential in human breast cancer (30,34), gastric carcinoma (35), and colonic carcinoma (36,37), as well as in urothelial carcinoma (16,18). It has been suggested that CD44 not only functions as an adhesion protein but may also play an important role in cytoskeleton-mediated cellular signals, suggesting a possible interaction between CD44 and CK20 at the cellular level.…”

mentioning

confidence: 99%

Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia

et al. 2000

View full text Add to dashboard Cite

The aim of this study was to assess the relationship of immunoreactivity of cytokeratin 20 (CK20) and CD44 across the spectrum of urothelial neoplasia using the WHO/ISUP consensus classification. A total of 120 papillary urothelial pTa and pT1 tumors (8 papillomas, 8 neoplasms of low malignant potential, and 42 low-grade and 62 high-grade carcinomas) were immunostained by using CK20 and CD44 antibodies. The relationships of tumor grade, pathologic stage, recurrences, and progression in stage with CK20 and CD44 immunoreactivity were assessed. WHO/ISUP grade correlated with tumor stage (P < 0.005), recurrence (P ‫؍‬ 0.02), and progression in stage (P ‫؍‬ 0.031). Normal urothelium showed CK20 immunoreactivity restricted to a few umbrella cells. Expression of CD44 in normal urothelium was restricted to the basal cell layer. Loss of CD44 immunoreactivity and increasing CK20 positivity were significantly associated with increasing tumor grade and stage (P < 0.005). An inverse relationship was observed in the staining patterns of CK20 and CD44 within individual cases, as well as in the aggregate data, with 79.2% of tumors with CD44 loss showing CK20 positivity (P < 0.001). In conclusion, CK20 and CD44 immunoreactivity are significantly related to the WHO/ISUP grade and to each other, and our data suggest their potential combined utility in predicting biologic behavior in patients with papillary urothelial pTa and pT1 neoplasms.

show abstract

“…Some studies have suggested that the expression of certain variant exons resulted in increased tumor progression, [21][22][23] while others have reported that there was no correlation. 24, 25 Reeder et al 15 reported that the expression of antisense variant exon 6 (exon v6) in a colon cancer cell line, HT29, reduced hepatic colonization and growth in an incisional wound site. Introduction of antisense exon v6 is capable of suppressing only the expression of CD44 variants containing exon v6.…”

mentioning

confidence: 99%

Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells

et al. 2000

View full text Add to dashboard Cite

CD44V6 expression in human colorectal carcinoma

Cited by 60 publications

References 40 publications

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia

Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells

Contact Info

Product

Resources

About